Squamous Cell Head and Neck Carcinoma Clinical Trial
Official title:
Hematologic Toxicity Observation of the TPF Medical Protocol. Description of the Impact of Febrile Neutropenia in Patients Who Receive the Chemotherapy of the TPF Medical Protocol in Head and Neck Cell Carcinoma
The ending of this study is to describe the effect of febrile neutropenia on patients who receive a chemotherapy by docetaxel+cisplatin+fluorouracil(TPF).
In this study we will describe
- habits of medical staff in prescription of growth factors or antibiotic prophylaxis
- ratio of patients treated by growth factors in primary or secondary prophylaxis
- ratio of patients treated in primary prophylaxis who present a febrile neutropenia
- ratio of patients who need to be hospitalized and the duration of those
hospitalizations.
- causes of lateness, of decreasing, and of stop of chemotherapy
- antibiotic and growth factors prophylaxis tolerance .
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT01289522 -
Chemotherapy With Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
|
Phase 2 | |
| Completed |
NCT01233843 -
Chemoradiotherapy HNSCC, Randomized Study, Docetaxel,Cisplatin, 5FU,Erbitux.
|
Phase 3 | |
| Withdrawn |
NCT03673735 -
Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC
|
Phase 3 | |
| Terminated |
NCT00408252 -
Efficacy of SU 011248 in Head And Neck Carcinoma
|
Phase 2 |